Fenofibrate Capsules

This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.

The main ingredient is fenofibrate.

Fenofibrate capsules are capsules, and the contents are white or off-white crystalline powder.

This product is used to treat hyperlipidemia (type IIa), endogenous hypertriglyceridemia, simple type (type IV) and mixed type (type IIb and III) in adults who are not well treated with dietary control therapy, especially when blood cholesterol continues to rise after dietary control, or there are other concurrent risk factors.

The drug can be taken for a long time with dietary control, and the efficacy should be monitored regularly. 1. Only one 200mg micronized capsule of Liping needs to be taken daily, with meals. 2. When cholesterol levels are normal, it is recommended to reduce the dose.

1. When used in combination with other fibrates, muscle dysfunction (diffuse pain, tenderness, muscle weakness) and rare severe rhabdomyolysis have been reported. Most of these adverse reactions are reversible after discontinuation of the drug (see the warning section for details). 2. Other less common, moderate adverse reactions have also been reported: (1) gastric or intestinal digestive dysfunction, such as dyspepsia; (2) elevated transaminases (see the precautions section for details). 3. Occasionally allergic skin reactions, such as rash, itching, urticaria, or photosensitivity reactions have been reported. In some cases, even after discontinuation of the drug for several months, erythema, papules, rashes, and eczema may still occur when the skin is exposed to sunlight or artificial ultraviolet rays. There are currently no long-term comparative studies to fully evaluate adverse reactions, especially the risk of gallstones.

1. Patients who are allergic to fenofibrate are contraindicated; 2. Patients with impaired liver function are contraindicated; 3. Patients with impaired renal function (see the warning section for details); 4. It is known that phototoxicity or photosensitivity reactions may occur when fenofibrate or drugs with similar structures, especially ketoprofen, are used during treatment; 5. It is contraindicated when used in combination with other fibrates (see the drug interactions section for details); 6. It is contraindicated in children. This drug is generally not recommended for use in combination with HMC-CoA reductase inhibitors (see the drug interactions section for details) and should not be used during lactation (see the pregnancy and lactation section for details).

Precautions for children: Children are prohibited from taking this product. Precautions for pregnancy and lactation: Precautions for pregnant women and lactating women are prohibited. Precautions for the elderly: The clearance rate of this product after a single oral dose is similar to that of adults, but if there is renal dysfunction, the dosage of this product should be appropriately reduced.

Concomitant use of other fibrates with the following drugs is contraindicated: Increased incidence of adverse reactions such as rhabdomyolysis and pharmacodynamic antagonism between the two molecules. Concomitant use of drugs not recommended HMG-CoA reduction enzyme inhibitors: Increased incidence of muscle adverse reactions such as rhabdomyolysis. Drugs to be used with caution Oral anticoagulants: Increased risk of bleeding after concomitant use of oral anticoagulants (due to their displacement reaction with plasma proteins). Check and monitor INR more frequently. Adjust the dose of oral anticoagulants during treatment with fenofibrate and after 8 days of discontinuation.

Store in a dry place.

0.1g

36 months.

Shaanxi Traditional Chinese Medicine Research Institute Hantang Pharmaceutical C O., Ltd.

• Founded in:

  1994-10-24

• Address:

  No. 18, Caotang 4th Road, Caotang Science and Technology Industrial Base, High-tech Zone, Xi'an, Shaanxi Province

• Tax NO.:

  91610000H04105014X

• Registered Funds:

  61.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view